<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500057</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB Protocol# 20111638</org_study_id>
    <nct_id>NCT01500057</nct_id>
  </id_info>
  <brief_title>Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia</brief_title>
  <official_title>An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooklyn Urology Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Medical Systems</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Richard Wolf Medical Instruments Corporation (RWMIC)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooklyn Urology Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 4, prospective, open-label, randomized study of Greenlight XPS Laser versus
      BiVAP Saline Vaporization of the prostate in men with symptomatic Benign Prostatic
      Hyperplasia (BPH). The study consists of a screening phase, treatment, followed by follow-up
      visits at 1 week, 4 weeks, 3 months, 6 months, and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">October 10, 2016</completion_date>
  <primary_completion_date type="Actual">October 10, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in American Urological Association Symptom Score</measure>
    <time_frame>Baseline and 12 months</time_frame>
    <description>The American Urological Association Symptom Score range is 0-35 with 35 being the most severe urinary symptoms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to 12 Months in Maximum Urinary Flow Rate (Qmax)</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>maximum urinary flow rate was measures using uroflow device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 12 Months in Post Void Residual Volume</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>post void residual was measured using a bladder scan device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <arm_group>
    <arm_group_label>Greenlight XPS Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Greenlight XPS Laser of the prostate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BiVAP Saline Vaporization</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BiVAP Saline Vaporization of the prostate</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Greenlight XPS Laser</intervention_name>
    <description>Treatment of BPH with Greenlight XPS laser</description>
    <arm_group_label>Greenlight XPS Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BiVAP Saline Vaporization of the prostate</intervention_name>
    <description>treatment of BPH with BiVAP Saline Vaporization</description>
    <arm_group_label>BiVAP Saline Vaporization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male over the age of 18 years

          -  present with symptomatic/ obstructive symptoms secondary to PBH requiring surgical
             intervention

          -  subjects must read, understand and sign the Informed Consent

          -  AUA ≥ 15

          -  Qmax &lt; 15mL/sec

          -  Stopped BPH medication. Alpha blockers 15 days 5-α-reductase 3 months

          -  Prostate volume ≥ 30g

        Exclusion Criteria:

          -  PVR &gt; 300ml

          -  Current urine retention

          -  Previous surgical or invasive treatments (TURP, TUMT, TUNA)

          -  PSA ≥ 4 (must have negative biopsy within last 12 months)

          -  Neurogenic bladder

          -  Obstruction due to urethral stricture

          -  Any disorder or condition of the subject that the investigator believes will counter
             indicate their inclusion in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2011</study_first_submitted>
  <study_first_submitted_qc>December 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 26, 2011</study_first_posted>
  <results_first_submitted>April 13, 2018</results_first_submitted>
  <results_first_submitted_qc>April 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2018</results_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooklyn Urology Research Group</investigator_affiliation>
    <investigator_full_name>Ivan Grunberger, MD</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>enlarged prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Greenlight XPS Laser</title>
          <description>Greenlight XPS Laser of the prostate
Greenlight XPS Laser: Treatment of BPH with Greenlight XPS laser</description>
        </group>
        <group group_id="P2">
          <title>BiVAP Saline Vaporization</title>
          <description>BiVAP Saline Vaporization of the prostate
BiVAP Saline Vaporization of the prostate: treatment of BPH with BiVAP Saline Vaporization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Greenlight XPS Laser</title>
          <description>Greenlight XPS Laser of the prostate
Greenlight XPS Laser: Treatment of BPH with Greenlight XPS laser</description>
        </group>
        <group group_id="B2">
          <title>BiVAP Saline Vaporization</title>
          <description>BiVAP Saline Vaporization of the prostate
BiVAP Saline Vaporization of the prostate: treatment of BPH with BiVAP Saline Vaporization</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.5" spread="8.1"/>
                    <measurement group_id="B2" value="65.5" spread="10.0"/>
                    <measurement group_id="B3" value="67.4" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in American Urological Association Symptom Score</title>
        <description>The American Urological Association Symptom Score range is 0-35 with 35 being the most severe urinary symptoms</description>
        <time_frame>Baseline and 12 months</time_frame>
        <population>All people who completed the study and had data available</population>
        <group_list>
          <group group_id="O1">
            <title>Greenlight XPS Laser</title>
            <description>Greenlight XPS Laser of the prostate
Greenlight XPS Laser: Treatment of BPH with Greenlight XPS laser</description>
          </group>
          <group group_id="O2">
            <title>BiVAP Saline Vaporization</title>
            <description>BiVAP Saline Vaporization of the prostate
BiVAP Saline Vaporization of the prostate: treatment of BPH with BiVAP Saline Vaporization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in American Urological Association Symptom Score</title>
          <description>The American Urological Association Symptom Score range is 0-35 with 35 being the most severe urinary symptoms</description>
          <population>All people who completed the study and had data available</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.7" spread="9.0"/>
                    <measurement group_id="O2" value="-10.5" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to 12 Months in Maximum Urinary Flow Rate (Qmax)</title>
        <description>maximum urinary flow rate was measures using uroflow device</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>all participants who completed the study and have available data</population>
        <group_list>
          <group group_id="O1">
            <title>Greenlight XPS Laser</title>
            <description>Greenlight XPS Laser of the prostate
Greenlight XPS Laser: Treatment of BPH with Greenlight XPS laser</description>
          </group>
          <group group_id="O2">
            <title>BiVAP Saline Vaporization</title>
            <description>BiVAP Saline Vaporization of the prostate
BiVAP Saline Vaporization of the prostate: treatment of BPH with BiVAP Saline Vaporization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Maximum Urinary Flow Rate (Qmax)</title>
          <description>maximum urinary flow rate was measures using uroflow device</description>
          <population>all participants who completed the study and have available data</population>
          <units>ml/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="8.6"/>
                    <measurement group_id="O2" value="2.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 12 Months in Post Void Residual Volume</title>
        <description>post void residual was measured using a bladder scan device</description>
        <time_frame>baseline and 12 months</time_frame>
        <population>all participants who completed the study and have available data</population>
        <group_list>
          <group group_id="O1">
            <title>Greenlight XPS Laser</title>
            <description>Greenlight XPS Laser of the prostate
Greenlight XPS Laser: Treatment of BPH with Greenlight XPS laser</description>
          </group>
          <group group_id="O2">
            <title>BiVAP Saline Vaporization</title>
            <description>BiVAP Saline Vaporization of the prostate
BiVAP Saline Vaporization of the prostate: treatment of BPH with BiVAP Saline Vaporization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 12 Months in Post Void Residual Volume</title>
          <description>post void residual was measured using a bladder scan device</description>
          <population>all participants who completed the study and have available data</population>
          <units>ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.9" spread="104.0"/>
                    <measurement group_id="O2" value="-36.7" spread="122.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Greenlight XPS Laser</title>
          <description>Greenlight XPS Laser of the prostate
Greenlight XPS Laser: Treatment of BPH with Greenlight XPS laser</description>
        </group>
        <group group_id="E2">
          <title>BiVAP Saline Vaporization</title>
          <description>BiVAP Saline Vaporization of the prostate
BiVAP Saline Vaporization of the prostate: treatment of BPH with BiVAP Saline Vaporization</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urethral stricture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>urinary retention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ivan Grunberger, M.D. Medical Director</name_or_title>
      <organization>Brooklyn Urology Research Group</organization>
      <phone>718-230-7788</phone>
      <email>ivg9002@nyp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

